European Archives - Page 581 of 1054 - European Medical Journal

hematology 8.1 featured image

Coagulopathy and Hyperinflammation in COVID-19

Clinical complications of COVID-19 include myocarditis, acute myocardial infarction, heart failure, venous thromboembolism, and cerebrovascular events…

EHA 2020 Interview: Prof Margarita Guevova

Prof Margarita Guevova | EHA Chair of European Board for Accreditation in HematologyNational Specialised Hospital for Active Treatment…

EHA 2020 Interview: Prof Antonio Almeida

Prof Antonio Almeida | European Hematology Association (EHA) Chair of the Curriculum CommitteeHead of Haematology, Hospital da Luz Lisboa…

EHA 2020 Interview: Dr Noémi Roy

Dr Noémi Roy | European Hematology Association (EHA) Guidelines Committee ChairConsultant Haematologist at Department of Haematology…

EHA 2020 Interview: Roundtable Interview with Dr Alba Maiques-Diaz and Dr Anna Kabanova

Roundtable interview with Dr Alba Maiques-Diaz and Dr Anna Kabanova

hematology 8.1 featured image

Paused Transcription: A Novel MIR139-Silencing Mechanism Downstream of MLL-AF9 in Acute Myeloid Leukaemia

The expression and tight regulation of microRNA is essential for haematopoiesis and the prevention of leukaemia…

Doing More for Patients with Immune Thrombocytopenia

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice

The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…

hematology 8.1 featured image

EMJ Hematology 8.1 2020

Featuring an independent review of the European Hematology Association (EHA) Virtual Congress 2020, alongside excellent articles presenting clinical…

hematology 8.1 featured image

Gene Therapy For Fanconi Anaemia: A Report on Outcomes in Nine Patients

Fanconi anaemia (FA) is a rare, inherited bone marrow failure syndrome, for which the only available curative treatment is haematopoietic cell transplant…

hematology 8.1 featured image

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?

This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…